文献速递白血病

尼洛替尼用于伊马替尼停药后未获无治疗缓解的慢性髓性白血病患者的疗效与安全性:法国Nilo post-STIM研究结果

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
PubMed 文献 · Br J Haematol · 2023-04-02

该前瞻性研究纳入2013至2018年间31例伊马替尼停药后出现分子学复发(MRec)的慢性期慢性髓性白血病(CML)患者,评估尼洛替尼(300 mg每日两次)的疗效与安全性。7例(23%)在中位2个月后发生导致停药的严重不良事件;23例接受2年尼洛替尼治疗的患者中22例维持分子学缓解至少1年(中位22个月)后停药,停药后24和48个月的无治疗缓解(TFR)率分别为59.1%(95%CI 41.7%-83.7%)和42.1%(95%CI 25%-71%)。

要点

  • 31例伊马替尼停药后分子学复发的慢性期CML患者接受尼洛替尼300 mg每日两次治疗。
  • 7例(23%)在中位2个月后发生导致停药的严重不良事件。
  • 23例治疗2年者中22例维持分子学缓解至少1年后停药,停药后24和48个月TFR率分别为59.1%和42.1%。

核心结论

  • 在伊马替尼停药后出现分子学复发的慢性期CML患者中,尼洛替尼治疗可使多数达到2年治疗且持续MR4.5至少1年的患者再次尝试停药,停药后24和48个月TFR率分别为59.1%(95%CI 41.7%-83.7%)和42.1%(95%CI 25%-71%)。

研究设计与样本

  • 前瞻性研究,纳入2013至2018年间31例伊马替尼停药后出现分子学复发的慢性期CML患者,评估尼洛替尼(300 mg每日两次)的疗效与安全性,并分析治疗2年且持续MR4.5至少1年者再次停药后的TFR概率。

主要发现

  • 31例患者中7例(23%)在中位2个月尼洛替尼治疗后发生导致停药的严重不良事件。
  • 1例患者因便利原因被排除出研究。
  • 23例接受2年尼洛替尼治疗的患者中,22例维持分子学缓解至少1年(中位22个月)并停止尼洛替尼。
  • 尼洛替尼停药后24和48个月TFR率分别为59.1%(95%CI 41.7%-83.7%)和42.1%(95%CI 25%-71%)。

关键数值与推荐

  • 尼洛替尼给药方案为300 mg每日两次。
  • 再次停药条件为接受尼洛替尼治疗2年且持续MR4.5至少1年。
  • 尼洛替尼停药后24个月TFR率为59.1%(95%CI 41.7%-83.7%),48个月TFR率为42.1%(95%CI 25%-71%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular recurrence (MRec) occurs in about half of all patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitors (TKI) in sustained deep molecular response. A second TKI discontinuation has been attempted in some patients who regain the discontinuation criteria after resuming treatment. Nilotinib treatment affords faster and deeper molecular responses than imatinib as first-line therapy. We prospectively evaluated the efficacy and safety of nilotinib (300 mg twice daily) in chronic-phase CML patients who experienced MRec, after imatinib discontinuation and analysed the probability of TFR after a new attempt in patients treated for 2 years with sustained MR4.5 for at least 1 year. A total of 31 patients were included in the study between 2013 and 2018. Seven (23%) patients experienced serious adverse events after a median of 2 months of nilotinib treatment leading to discontinuation of treatment. One patient was excluded from the study for convenience. Among the 23 patients treated for 2 years with nilotinib, 22 maintained their molecular response for at least 1 year (median: 22 months) and stopped nilotinib. The TFR rates at 24 and 48 months after nilotinib discontinuation were 59.1% (95% confidence interval [CI]: 41.7%-83.7%) and 42.1% (95% CI: 25%-71%) respectively (NCT #01774630).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dulucq S, Rigal-Huguet F, Nicolini FE, et al. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study. Br J Haematol. 2023. PMID: 37004981. doi:10.1111/bjh.18796

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。